aminosalicylic acid has been researched along with Colitis Gravis in 47 studies
Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.
4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Oral 5-aminosalicylic acid (5-ASA) has proven an effective maintenance therapy of ulcerative colitis and may also be useful in Crohn's disease, but its safety in pregnancy has not been established." | 9.07 | Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. ( Greenberg, GR; Habal, FM; Hui, G, 1993) |
| "After 12 months in a group of patients who took tianeptine decrease in anxiety (from 20." | 5.15 | [Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission]. ( Chojnacki, C; Chojnacki, J; Florkowski, A; Klupinska, G; Pawłowicz, M; Wachowska-Kelly, P; Walecka-Kapica, E, 2011) |
| " The recommendations encompass pretreatment evaluation; medical management of active IBD; medical management of IBD in remission; management of IBD during the periconception period and pregnancy; surveillance strategies for colitis-associated cancer; monitoring side effects of thiopurines and methotrexate; and infections in IBD." | 5.12 | Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia. ( Ahuja, V; Andoh, A; Chen, M; Han, DS; Hibi, T; Hilmi, IN; Hu, PJ; Jeen, YT; Kim, HJ; Leung, WK; Matsuoka, K; Ng, SC; Ooi, CJ; Qian, J; Ran, Z; Sollano, J; Suzuki, Y; Watanabe, M; Wei, SC; Wu, K; Yang, SK, 2021) |
| "Oral 5-aminosalicylic acid (5-ASA) has proven an effective maintenance therapy of ulcerative colitis and may also be useful in Crohn's disease, but its safety in pregnancy has not been established." | 5.07 | Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course. ( Greenberg, GR; Habal, FM; Hui, G, 1993) |
| "Forty patients with active ulcerative colitis were randomly assigned to receive either 4 g of oral enterically coated 4-aminosalicylic acid (para-aminosalicylic acid) or placebo." | 2.67 | Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid. ( Davis, ND; Ginsberg, AL; Nochomovitz, LE, 1992) |
| "4-Aminosalicylic acid enemas are a safe and effective means of treating left-sided ulcerative colitis." | 2.66 | Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial. ( Beck, LS; Ginsberg, AL; McIntosh, TM; Nochomovitz, LE, 1988) |
| "5-Aminosalicylic acid (5-ASA) is the active component of Salazopyrin and induces a prompt and excellent improvement, when administered as high dosage enema, in patients suffering from active ulcerative colitis." | 2.65 | A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis. ( Bazzocchi, G; Bertoni, F; Brignola, C; Campieri, M; Labò, G; Lanfranchi, GA; Minguzzi, MR, 1984) |
| " Probiotics such as bifid triple viable (BTV) could reduce drug-induced adverse reactions and has a good clinical effect on UC." | 2.61 | Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis. ( Cai, QQ; Chen, MY; Chen, XL; Li, HB; Qiu, ZW; Tang, HM; Zhuang, KH, 2019) |
| "We conducted a meta-analysis to evaluate the effect of probiotic combined with aminosalicylic on induction remission maintenance treatment of ulcerative colitis (UC)." | 2.61 | Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial. ( Jiang, Z; Peng, L; Wang, A; Zhong, Y, 2019) |
| " However, KFXL combined with ASA did not increase the adverse event incidence [RR = 0." | 2.58 | Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis. ( Cai, QQ; Chen, MY; Chen, XL; Li, DT; Li, HB; Qiu, ZW; Tang, HM, 2018) |
| "UC related colorectal cancer develop in an unpredictable manner with respect to disease duration and site questioning the validity of strict screening protocol." | 2.53 | Inflammatory bowel disease in India - Past, present and future. ( Ray, G, 2016) |
| "The proportion of women with Crohn's disease and ulcerative colitis on any treatment during pregnancy was 56." | 1.62 | The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing. ( Bateman, BT; Brill, G; Bröms, G; Desai, RJ; Friedman, S; Hernandez-Diaz, S; Huybrechts, KF; Kim, SC; Wood, ME, 2021) |
| "Clinical relapse was defined as need for induction treatment, treatment escalation, hospitalization or surgery." | 1.43 | Mucosal Healing in Ulcerative Colitis--When Zero is Better. ( Boal Carvalho, P; Cotter, J; Dias de Castro, F; Moreira, MJ; Rosa, B, 2016) |
| "Thirty to forty-five percent of ulcerative colitis (UC) patients show non-adherence to aminosalicylates, and non-adherence has been reported to increase the risk of clinical relapse." | 1.39 | Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study. ( Hibi, T; Iwao, Y; Kawakami, A; Kazuma, K; Naganuma, M; Nishigaki, M; Sanada, H; Tanaka, M; Yamamoto-Mitani, N, 2013) |
| "The birth outcomes in women with ulcerative colitis are examined in a nationwide, Danish, cohort of women based on data from the Danish National Hospital Discharge Registry and the Danish Medical Birth Registry, and within a Hungarian case-control data set." | 1.37 | Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy. ( Nørgård, BM, 2011) |
| " A pharmacokinetic comparison of polymer and SASP showed similar deliveries of 5-ASA and metabolites to the lower bowel, blood, and urine of orally dosed rats." | 1.27 | A polymeric drug for treatment of inflammatory bowel disease. ( Brown, JP; McGarraugh, GV; Onderdonk, AB; Parkinson, TM; Wingard, RE, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (21.28) | 18.7374 |
| 1990's | 12 (25.53) | 18.2507 |
| 2000's | 2 (4.26) | 29.6817 |
| 2010's | 19 (40.43) | 24.3611 |
| 2020's | 4 (8.51) | 2.80 |
| Authors | Studies |
|---|---|
| Li, F | 1 |
| Wu, G | 1 |
| Zheng, H | 1 |
| Wang, L | 1 |
| Zhao, Z | 1 |
| Chen, Y | 3 |
| Wang, P | 3 |
| Zhang, Y | 3 |
| Du, XY | 3 |
| Zhang, YJ | 3 |
| Viscido, A | 1 |
| Latella, G | 1 |
| Frieri, G | 1 |
| Gisbert, JP | 1 |
| Chaparro, M | 1 |
| Chen, MY | 2 |
| Qiu, ZW | 2 |
| Tang, HM | 2 |
| Zhuang, KH | 1 |
| Cai, QQ | 2 |
| Chen, XL | 2 |
| Li, HB | 2 |
| Chateau, T | 1 |
| Feakins, R | 1 |
| Marchal-Bressenot, A | 1 |
| Magro, F | 1 |
| Danese, S | 1 |
| Peyrin-Biroulet, L | 1 |
| Ran, Z | 1 |
| Wu, K | 1 |
| Matsuoka, K | 1 |
| Jeen, YT | 1 |
| Wei, SC | 1 |
| Ahuja, V | 1 |
| Chen, M | 1 |
| Hu, PJ | 1 |
| Andoh, A | 1 |
| Kim, HJ | 1 |
| Yang, SK | 1 |
| Watanabe, M | 1 |
| Ng, SC | 1 |
| Hibi, T | 2 |
| Hilmi, IN | 1 |
| Suzuki, Y | 1 |
| Han, DS | 1 |
| Leung, WK | 1 |
| Sollano, J | 1 |
| Ooi, CJ | 1 |
| Qian, J | 1 |
| Bröms, G | 1 |
| Friedman, S | 1 |
| Kim, SC | 1 |
| Wood, ME | 1 |
| Hernandez-Diaz, S | 1 |
| Brill, G | 1 |
| Bateman, BT | 1 |
| Huybrechts, KF | 1 |
| Desai, RJ | 1 |
| Li, DT | 1 |
| Singh, S | 1 |
| Proudfoot, JA | 1 |
| Dulai, PS | 1 |
| Jairath, V | 1 |
| Fumery, M | 1 |
| Xu, R | 1 |
| Feagan, BG | 2 |
| Sandborn, WJ | 1 |
| Peng, L | 1 |
| Zhong, Y | 1 |
| Wang, A | 1 |
| Jiang, Z | 1 |
| Fuchs, S | 1 |
| Sawas, N | 1 |
| Staedler, N | 1 |
| Schubert, DA | 1 |
| D'Andrea, A | 1 |
| Zeiser, R | 1 |
| Piali, L | 1 |
| Hruz, P | 1 |
| Frei, AP | 1 |
| East, JE | 1 |
| Boyapati, RK | 1 |
| Torres, J | 1 |
| Parker, CE | 1 |
| MacDonald, JK | 1 |
| Chande, N | 1 |
| Buchner, AM | 1 |
| Lichtenstein, GR | 1 |
| Olaisen, M | 1 |
| Fossmark, R | 1 |
| Kawakami, A | 2 |
| Tanaka, M | 2 |
| Nishigaki, M | 2 |
| Yoshimura, N | 1 |
| Suzuki, R | 1 |
| Maeda, S | 1 |
| Kunisaki, R | 1 |
| Yamamoto-Mitani, N | 2 |
| dos Santos, LC | 1 |
| Costa, AV | 1 |
| Lopes, LG | 1 |
| Leonel, AJ | 1 |
| Aguilar, EC | 1 |
| Noviello, Mde L | 1 |
| Ferrari, Mde L | 1 |
| Alvarez-Leite, JI | 1 |
| Boal Carvalho, P | 1 |
| Dias de Castro, F | 1 |
| Rosa, B | 1 |
| Moreira, MJ | 1 |
| Cotter, J | 1 |
| Takahashi, F | 1 |
| Tominaga, K | 1 |
| Kanamori, A | 1 |
| Takenaka, K | 1 |
| Hoshino, A | 1 |
| Sugaya, T | 1 |
| Nakano, M | 1 |
| Hiraishi, H | 1 |
| Ray, G | 1 |
| Glickman, JN | 1 |
| Odze, RD | 1 |
| Baars, JE | 1 |
| Zelinkova, Z | 1 |
| Mensink, PB | 1 |
| Markus, T | 1 |
| Looman, CW | 1 |
| Kuipers, EJ | 1 |
| Van Der Woude, CJ | 1 |
| Chojnacki, C | 1 |
| Walecka-Kapica, E | 1 |
| Klupinska, G | 1 |
| Pawłowicz, M | 1 |
| Florkowski, A | 1 |
| Wachowska-Kelly, P | 1 |
| Chojnacki, J | 1 |
| Nørgård, BM | 1 |
| Naganuma, M | 1 |
| Iwao, Y | 1 |
| Sanada, H | 1 |
| Kazuma, K | 1 |
| LAMBLING, A | 1 |
| GOUGIS, M | 1 |
| BERNIER, JJ | 1 |
| Brown, JP | 1 |
| McGarraugh, GV | 1 |
| Parkinson, TM | 1 |
| Wingard, RE | 1 |
| Onderdonk, AB | 1 |
| Campieri, M | 1 |
| Lanfranchi, GA | 1 |
| Bertoni, F | 1 |
| Brignola, C | 1 |
| Bazzocchi, G | 1 |
| Minguzzi, MR | 1 |
| Labò, G | 1 |
| Selby, WS | 1 |
| Bennett, MK | 1 |
| Jewell, DP | 2 |
| Marteau, P | 1 |
| Halphen, M | 1 |
| Habal, FM | 1 |
| Hui, G | 1 |
| Greenberg, GR | 1 |
| Bonner, GF | 1 |
| Beeken, W | 1 |
| Howard, D | 1 |
| Bigelow, J | 1 |
| Trainer, T | 1 |
| Roy, M | 1 |
| Thayer, W | 1 |
| Wild, G | 1 |
| Ginsberg, AL | 3 |
| Davis, ND | 1 |
| Nochomovitz, LE | 2 |
| Lahoti, D | 1 |
| Broor, SL | 1 |
| Gaffney, P | 1 |
| Doyle, C | 1 |
| Gaffney, A | 1 |
| Eliakim, R | 1 |
| Karmeli, F | 1 |
| Chorev, M | 1 |
| Okon, E | 1 |
| Rachmilewitz, D | 1 |
| Lémann, M | 1 |
| O'Donnell, LJ | 1 |
| Arvind, AS | 1 |
| Hoang, P | 1 |
| Cameron, D | 1 |
| Talbot, IC | 1 |
| Lennard-Jones, JE | 1 |
| Farthing, MJ | 1 |
| Bruckstein, AH | 1 |
| Hartmann, F | 1 |
| Plauth, M | 1 |
| Sharma, MP | 1 |
| Duphare, HV | 1 |
| Friedman, G | 1 |
| Peskar, BM | 1 |
| Beck, LS | 1 |
| McIntosh, TM | 1 |
| Meyers, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Randomized, Open-label, Parallel-group, Multicenter Trial to Evaluate the Safety and Efficacy of Infliximab (REMICADE�) in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis[NCT00336492] | Phase 3 | 60 participants (Actual) | Interventional | 2006-09-30 | Completed | ||
| [NCT00004810] | Phase 2 | 30 participants | Interventional | 1996-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Range is 0 to 12 points, where 0 is the least disease activity, and 12 is the most disease activity. Clinical response at Week 8 is defined as a decrease from baseline in the Mayo score(based on symptoms of ulcerative colitis) by >=30% and >= 3 points, with a decrease in the rectal bleeding subscore >=1 or a rectal bleeding subscore of 0 or 1. Treatment failure rules (patients who discontinued study agent due to lack of therapeutic effect, had a colectomy or ostomy, or had protocol-prohibited medication changes) were applied to determine the final clinical response status for each patient. (NCT00336492)
Timeframe: Week 8
| Intervention | Participants (Number) |
|---|---|
| Infliximab 5 mg/kg | 44 |
Range is 0 to 85 points, where 0 is the least disease activity, and 85 is the most disease activity. Remission is a score <10. In addition to the PUCAI remission status, treatment failure rules (patients who discontinued study agent due to lack of therapeutic effect, had a colectomy or ostomy, had protocol-prohibited medication changes, or stepped up) were applied to determine the final PUCAI. (NCT00336492)
Timeframe: Week 54
| Intervention | Participants (Number) |
|---|---|
| 5 mg/kg Infliximab Every 8 Wks | 8 |
| 5 mg/kg Infliximab Every 12 Wks | 4 |
14 reviews available for aminosalicylic acid and Colitis Gravis
| Article | Year |
|---|---|
Efficacy and safety of bifid triple viable plus aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Combined Modality Therapy; Humans; Probiotics; Randomized | 2019 |
Histological Remission in Ulcerative Colitis: Under the Microscope Is the Cure.
Topics: Aminosalicylic Acid; Antibodies, Monoclonal, Humanized; Biological Products; Colitis, Ulcerative; Co | 2020 |
Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology practice recommendations for medical management and monitoring of inflammatory bowel disease in Asia.
Topics: Adrenal Cortex Hormones; Aminosalicylic Acid; Asia; Azathioprine; Colitis, Ulcerative; Crohn Disease | 2021 |
Efficacy and safety of Kangfuxin liquid combined with aminosalicylic acid for the treatment of ulcerative colitis: A systematic review and meta-analysis.
Topics: Aminosalicylic Acid; Antitubercular Agents; Colitis, Ulcerative; Cytokines; Drug Therapy, Combinatio | 2018 |
No Benefit of Concomitant 5-Aminosalicylates in Patients With Ulcerative Colitis Escalated to Biologic Therapy: Pooled Analysis of Individual Participant Data From Clinical Trials.
Topics: Aminosalicylic Acid; Antibodies, Monoclonal; Biological Therapy; Colitis, Ulcerative; Drug Therapy, | 2018 |
Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Humans; Probiotics; Publication Bias; Randomized Controlle | 2019 |
Controversies in Inflammatory Bowel Disease: Exploring Clinical Dilemmas Using Cochrane Reviews.
Topics: Administration, Oral; Aminosalicylic Acid; Colitis, Ulcerative; Colonic Neoplasms; Crohn Disease; Hu | 2019 |
Inflammatory bowel disease in India - Past, present and future.
Topics: Aminosalicylic Acid; Antitubercular Agents; Asia, Southeastern; Azathioprine; Biological Products; B | 2016 |
Current medical therapy for inflammatory bowel disease.
Topics: Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acid; Aminosalicylic Acids; Anti-In | 1996 |
New salicylate therapies for ulcerative colitis.
Topics: Administration, Oral; Administration, Rectal; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ul | 1990 |
[Aminosalicylates in the treatment of chronic inflammatory bowel diseases].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disease; Humans; Mesalamine; R | 1990 |
Topical salicylate therapy (4-ASA and 5-ASA enemas).
Topics: Administration, Topical; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Crohn Disea | 1989 |
Sulfasalazine and new analogues.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Clinical Trials as Topic; Colitis, Ulcerative; C | 1986 |
[Inhibition of intestinal leukotriene formation as a possible mechanism of action of sulfasalazine, 5-aminosalicylic acid and 4-aminosalicylic acid].
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Colitis, Ulcerative; Crohn Disease; Humans; Inte | 1988 |
11 trials available for aminosalicylic acid and Colitis Gravis
| Article | Year |
|---|---|
[Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission].
Topics: Adult; Aminosalicylic Acid; Antidepressive Agents, Tricyclic; Anxiety; Colitis, Ulcerative; Depressi | 2011 |
A double-blind clinical trial to compare the effects of 4-aminosalicylic acid to 5-aminosalicylic acid in topical treatment of ulcerative colitis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Biopsy; Clinical Trials as Topic; Colitis, Ulcerative; Co | 1984 |
Topical treatment of distal ulcerative colitis with 4-amino-salicylic acid enemas.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Double-Bli | 1984 |
[Comparative randomized open study of the efficacy and tolerance of enemas with 2 gr of 4-amino-salicylic acid (4-ASA) and 1 gr of 5-amino-salicylic acid (5-ASA) in distal forms of hemorrhagic rectocolitis].
Topics: Adult; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Endoscopy, Gastrointestinal; | 1995 |
Oral 5-aminosalicylic acid for inflammatory bowel disease in pregnancy: safety and clinical course.
Topics: Administration, Oral; Adult; Aminosalicylic Acid; Colitis, Ulcerative; Crohn Disease; Dose-Response | 1993 |
Controlled trial of 4-ASA in ulcerative colitis.
Topics: Aminosalicylic Acid; Biopsy; Colitis, Ulcerative; Feces; Female; Humans; Male; Middle Aged; Rectum | 1997 |
Placebo-controlled trial of ulcerative colitis with oral 4-aminosalicylic acid.
Topics: Administration, Oral; Adult; Aminosalicylic Acid; Biopsy; Colitis, Ulcerative; Double-Blind Method; | 1992 |
[4-ASA by oral administration in hemorrhagic rectocolitis: first controlled study].
Topics: Administration, Oral; Aminosalicylic Acid; Colitis, Ulcerative; Humans; Placebos | 1992 |
Double blind, controlled trial of 4-aminosalicylic acid and prednisolone enemas in distal ulcerative colitis.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Double-Blind Method; Drug Administration Schedule; Enema; | 1992 |
Sulfasalazine and new analogues.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Animals; Clinical Trials as Topic; Colitis, Ulcerative; C | 1986 |
Treatment of left-sided ulcerative colitis with 4-aminosalicylic acid enemas. A double-blind, placebo-controlled trial.
Topics: Adult; Aminosalicylic Acid; Aminosalicylic Acids; Clinical Trials as Topic; Colitis, Ulcerative; Dou | 1988 |
23 other studies available for aminosalicylic acid and Colitis Gravis
| Article | Year |
|---|---|
Synthesis, colon-targeted studies and pharmacological evaluation of an anti-ulcerative colitis drug 4-Aminosalicylic acid-β-O-glucoside.
Topics: Animals; Colitis, Ulcerative; Colon; Dose-Response Relationship, Drug; Glucosides; Male; Molecular S | 2016 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Comparison of effects of aminosalicylic acid, glucocorticoids and immunosuppressive agents on the expression of multidrug-resistant genes in ulcerative colitis.
Topics: Aminosalicylic Acid; ATP Binding Cassette Transporter, Subfamily B, Member 1; Colitis, Ulcerative; G | 2022 |
Topical Aminosalicylates and Histologic Healing in Ulcerative Colitis.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Humans; Mesalamine; Randomized Controlled Trials as Topic; | 2019 |
Are there reliable predictive factors of nonresponse to aminosalicylates in patients with ulcerative colitis?
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Case-Control Studies; Clinical Decision Rules; Co | 2019 |
The Patterns of Use of Medications for Inflammatory Bowel Disease During Pregnancy in the US and Sweden Are Changing.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Crohn Disease; Female; Gastrointestinal Agents; Humans; Im | 2021 |
High-dimensional single-cell proteomics analysis identifies immune checkpoint signatures and therapeutic targets in ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Antibodies, Monoclonal, Humanized; Colitis, Ulc | 2019 |
Editorial: mesalazine and mucosal microbiome in quiescent ulcerative colitis-what can we learn?
Topics: Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Compounding; | 2019 |
Editorial: mesalamine and mucosal microbiome in quiescent ulcerative colitis-what can we learn? Authors' reply.
Topics: Aminosalicylic Acid; Anti-Inflammatory Agents, Non-Steroidal; Colitis, Ulcerative; Drug Compounding; | 2019 |
A screening instrument to identify ulcerative colitis patients with the high possibility of current non-adherence to aminosalicylate medication based on the Health Belief Model: a cross-sectional study.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Cross-Sectional Studies; Health Knowledge, Attitudes, Prac | 2014 |
Combination of Azathioprine and Aminosalicylate Treatment Prevent Risk of Cardiovascular Disease in Women with Ulcerative Colitis by Reducing Inflammation.
Topics: Adult; Aminosalicylic Acid; Azathioprine; Biomarkers; Cardiovascular Diseases; Case-Control Studies; | 2015 |
Mucosal Healing in Ulcerative Colitis--When Zero is Better.
Topics: Adult; Age Factors; Aged; Aminosalicylic Acid; Analysis of Variance; Biological Products; Cohort Stu | 2016 |
Timing for dose-down of 5-ASA depends on mucosal status with ulcerative colitis.
Topics: Aminosalicylic Acid; Colitis, Ulcerative; Endoscopy, Gastrointestinal; Female; Humans; Intestinal Mu | 2016 |
Does rectal sparing ever occur in ulcerative colitis?
Topics: Administration, Oral; Administration, Topical; Adrenal Cortex Hormones; Aminosalicylic Acid; Colitis | 2008 |
High therapy adherence but substantial limitations to daily activities amongst members of the Dutch inflammatory bowel disease patients' organization: a patient empowerment study.
Topics: Activities of Daily Living; Adrenal Cortex Hormones; Adult; Aminosalicylic Acid; Colitis, Ulcerative | 2009 |
Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Topics: Adrenal Cortex Hormones; Adult; Aminosalicylic Acid; Anti-Inflammatory Agents; Anti-Inflammatory Age | 2011 |
Relationship between non-adherence to aminosalicylate medication and the risk of clinical relapse among Japanese patients with ulcerative colitis in clinical remission: a prospective cohort study.
Topics: Adult; Aminosalicylic Acid; Cohort Studies; Colitis, Ulcerative; Drug Administration Schedule; Femal | 2013 |
[The treatment of hemorrhagic rectocolitis (ulcerative colitis) by isoniazid with or without streptomycin and PAS].
Topics: Aminosalicylic Acid; Colitis; Colitis, Ulcerative; Isoniazid; Proctocolitis; Streptomycin | 1959 |
A polymeric drug for treatment of inflammatory bowel disease.
Topics: Aminosalicylic Acid; Animals; Biotransformation; Colitis, Ulcerative; Guinea Pigs; Intestines; Polym | 1983 |
Oral 4-ASA in ulcerative colitis.
Topics: Adult; Aminosalicylic Acid; Colitis, Ulcerative; Female; Humans; Male | 1992 |
Oral 4-aminosalicylic acid therapy in ulcerative colitis.
Topics: Administration, Oral; Aminosalicylic Acid; Colitis, Ulcerative; Heparin; Humans; Thromboembolism | 1992 |
Effect of drugs on colonic eicosanoid accumulation in active ulcerative colitis.
Topics: Adult; Aged; Aged, 80 and over; Aminosalicylic Acid; Aminosalicylic Acids; Anti-Inflammatory Agents, | 1992 |
4-Aminosalicylic acid enemas for ulcerative colitis.
Topics: Acute Disease; Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Enema; Humans; Pilot | 1989 |
The place of oral 5-aminosalicylic acid in the therapy of ulcerative colitis.
Topics: Aminosalicylic Acid; Aminosalicylic Acids; Colitis, Ulcerative; Humans | 1988 |